Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC).

Reviewer: S. Jack Wei, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de junio del 2003

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015